{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:44:22Z","timestamp":1776296662180,"version":"3.50.1"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To review cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) occurring in association with benign disease and to describe and compare the clinical course and outcome for patients with BRONJ and rheumatoid arthritis (RA) or osteoporosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We retrospectively reviewed observations of all patients referred for treatment and followup for BRONJ from January 2007 to December 2011. Only patients with malignant disease were excluded. Demographic data, medical history, maxillofacial findings, BRONJ treatment, and followup were reviewed for each case.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Over a 5-year period, we diagnosed 112 patients with BRONJ. Among these patients, 15 received bisphosphonate (BP) treatment for nonmalignant disease (mean age 65.7 \u00b1 19.8 yrs, 80% women). Patients received BP for a variety of reasons: 8 (53%) to prevent osteoporosis in association with underlying RA; 6 (40%) to prevent idiopathic osteoporosis; and 1 (7%) to treat ankle algodystrophy. The mean oral BP exposure period was 48.4 months (median 36 mo). In 13 cases (86.6%), BRONJ was diagnosed following dental extraction. Of the 8 patients with RA, 5 (62.5%) were taking prednisone at the time of the discovery of BRONJ. Major surgery, sequestrectomy, or alveolectomy was performed in 9 patients (60%), all of whom healed within 3 to 36 months (mean 11.5 mo). Comparative analysis of all the variables showed no statistically significant differences between patients with RA and others.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>ONJ is a rare adverse effect of BP therapy, especially when administered orally. Within the limits of our study, we were unable to demonstrate a difference in BRONJ disease spectrum, clinical course, or outcome between patients with and those without RA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.120810","type":"journal-article","created":{"date-parts":[[2013,3,16]],"date-time":"2013-03-16T07:42:35Z","timestamp":1363419755000},"page":"781-786","source":"Crossref","is-referenced-by-count":26,"title":["Osteonecrosis of the Jaw and Nonmalignant Disease: Is There an Association with Rheumatoid Arthritis?"],"prefix":"10.3899","volume":"40","author":[{"given":"G\u00e9raldine","family":"Lescaille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie E.","family":"Coudert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Baaroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Jos\u00e9","family":"Javelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Berdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Goudot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Az\u00e9rad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blandine","family":"Ruhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vianney","family":"Descroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2013,3,15]]},"reference":[{"key":"2018112909313803000_40.6.781.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.04.022"},{"key":"2018112909313803000_40.6.781.2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.2010.05771.x","article-title":"Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients","volume":"1218","author":"Hoff","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"2018112909313803000_40.6.781.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05768.x"},{"key":"2018112909313803000_40.6.781.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.01.003"},{"key":"2018112909313803000_40.6.781.5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0115"},{"key":"2018112909313803000_40.6.781.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-2013-y"},{"key":"2018112909313803000_40.6.781.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2010.11.002"},{"key":"2018112909313803000_40.6.781.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090455"},{"key":"2018112909313803000_40.6.781.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2010.05.009"},{"key":"2018112909313803000_40.6.781.10","doi-asserted-by":"publisher","DOI":"10.1186\/1746-160X-8-5"},{"key":"2018112909313803000_40.6.781.11","unstructured":"Agence Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments et des Produits de Sant\u00e9 Ventes de m\u00e9dicaments aux officines et aux h\u00f4pitaux en France \u2013 Chiffres-cl\u00e9s 2010 [Sales of medicines to pharmacies and hospitals in France \u2013 Key figures.] [Internet. Accessed Jan 31, 2013.] Available from: http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/c66c522fa172251d7588e4086475dd1b.pdf"},{"key":"2018112909313803000_40.6.781.12","first-page":"70","article-title":"Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population","volume":"35","author":"de Pablo","year":"2008","journal-title":"J Rheumatol"},{"issue":"Suppl","key":"2018112909313803000_40.6.781.13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.joms.2008.10.005","article-title":"Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Initial discovery and subsequent development","volume":"5","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg Suppl"},{"key":"2018112909313803000_40.6.781.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.10.008"},{"key":"2018112909313803000_40.6.781.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029199"},{"key":"2018112909313803000_40.6.781.16","doi-asserted-by":"publisher","DOI":"10.1186\/ar4061"},{"key":"2018112909313803000_40.6.781.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.34595"},{"key":"2018112909313803000_40.6.781.18","first-page":"384","article-title":"Multiple osteonecrosis of the jaw, oral bisphosphonate therapy and refractory rheumatoid arthritis (Pathological fracture associated with ONJ and BP use for osteoporosis)","volume":"26","author":"Grana","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909313803000_40.6.781.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0973-3"},{"key":"2018112909313803000_40.6.781.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2011.08.008"},{"key":"2018112909313803000_40.6.781.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2011.08.033"},{"key":"2018112909313803000_40.6.781.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.07.011"},{"key":"2018112909313803000_40.6.781.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2010.01778.x"},{"key":"2018112909313803000_40.6.781.24","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"2018112909313803000_40.6.781.25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.035295"},{"key":"2018112909313803000_40.6.781.26","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834518a3"},{"key":"2018112909313803000_40.6.781.27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn526"},{"key":"2018112909313803000_40.6.781.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2008.11.015"},{"key":"2018112909313803000_40.6.781.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2005.07.010"},{"key":"2018112909313803000_40.6.781.30","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2007.060514"},{"key":"2018112909313803000_40.6.781.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0384-2"},{"key":"2018112909313803000_40.6.781.32","doi-asserted-by":"publisher","DOI":"10.1902\/jop.2007.060239"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.120810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:24:31Z","timestamp":1543515871000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.120810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,15]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,1]]},"published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.3899\/jrheum.120810"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.120810","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,15]]}}}